Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $10.37M rose 46.6% year over year, ahead of the +11.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 24.7% from the prior quarter. Over 3 fiscal years it compounded at +8.4% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +46.6% holds above the trailing-twelve-month pace of +11.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$10.37M+24.7% QoQ
Last fiscal yearDec 2025
$27.65M-16.3% YoY
LTMSep 2026
$31.2M+11.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.6%——
1 year-16.3%——
3-year CAGR+8.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
27.65M USD
Year-over-year change
-16.3%
4-year CAGR
+72.3%

Stock-Based Compensation vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.4% is the 4th highest of 10, against a peer median of -5.5%.
  • Over three fiscal years its annual growth of +8.4% compares with a peer median of +6.1%.
AMLX Competitors
Stock-Based Compensation for AMLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PMNProMIS Neurosciences, Inc.LTM Jun 2026$857.38M USD+71257.3%+9.4%—
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M USD+4.4%+10.1%13.8%
DNLIDenali Therapeutics Inc.LTM Jun 2026$69.95M USD+39.2%-0.1%1941.0%
PRTAProthena Corporation plcLTM Mar 2026$33.61M USD-24.5%+6.3%58.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$31.2M USD+11.4%+8.4%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$26.2M USD-19.6%+5.9%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$10.6M USD+15.1%-14.3%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$9.79M USD-31.5%+8.6%—
CLNNClene Inc.LTM Mar 2026$7.45M USD-5.5%-9.2%5559.7%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
Peer median (excluding AMLX) —-5.5%+6.1%75.0%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Depreciation & Amortization52K487K1.09M904K525K
Deferred Income Tax00000
Stock-Based Compensation3.14M21.71M37.16M33.04M27.65M
Change in Working Capital4.6M(1.64M)(65.66M)(45.83M)(1.08M)
Accounts Receivables(144K)(15.31M)(24.74M)39.6M383K
Inventory0(9.77M)(73.13M)(9.25M)0
Accounts Payables670K1.85M15.88M(19.1M)580K
Other Working Capital4.07M21.58M16.33M(57.08M)(2.05M)
Other Non-Cash Items5.35M(2.06M)(9.94M)145.99M(5.7M)
Operating Cash Flow(74.8M)(179.87M)11.92M(167.65M)(123.34M)
Capital Expenditures(353K)(2.53M)(1.24M)(157K)(138K)
Acquisitions (Net)0236.46M000
Purchases of Investments(49.05M)(415.87M)(300.83M)(231.99M)(231.82M)
Sales of Investments3M179.41M394.12M344M246M
Other Investing Activities0(236.46M)0(36.2M)0
Investing Cash Flow(46.41M)(238.99M)92.05M75.65M14.04M
Debt Repayment25.9M0000
Common Stock Issued0432.45M6.86M2.13M260.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.39M)(658K)(3.32M)(1.78M)(3.36M)
Financing Cash Flow158.51M431.79M3.54M348K257.03M
Effect of Forex Changes13K(65K)160K(438K)1.07M
Net Change in Cash37.31M12.87M107.68M(92.08M)148.8M
Free Cash Flow(75.15M)(182.4M)10.68M(167.8M)(123.48M)

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.